Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Memory T Cell Subsets, Migration Patterns, and Tissue Residence

(2012) Scott N. Mueller et al.   Annual Review of Immunology

Phase I Trial of TGF- 2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine

(2011) J. Olivares et al.   CLINICAL CANCER RESEARCH

Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer

(2011) Neil Senzer et al.   MOLECULAR THERAPY

Different patterns of peripheral migration by memory CD4+ and CD8+ T cells

(2011) Thomas Gebhardt et al.   NATURE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus

(2009) Thomas Gebhardt et al.   NATURE IMMUNOLOGY